Monograph Details
|
|
Nutrition
> Obesity
|
|
BONTRIL PDM |
| Manufacturer |
|
Valeant Pharmaceuticals, Inc |
| Legal Classification |
|
CIII |
| Pharmacological Class |
|
Sympathomimetic. |
| Generic Name |
|
Phendimetrazine tartrate 35mg; scored tabs. |
| Also |
|
• BONTRIL SLOW RELEASE
|
| Indications |
|
Short-term adjunct in managing exogenous obesity. |
| Children |
|
Not recommended. |
| Adults |
|
35mg 2 or 3 times daily, 1 hour before meals; may reduce to 17.5mg/dose. Max 210mg/day in 3 evenly divided doses. |
| Contraindications |
|
Advanced arteriosclerosis. Cardiovascular disease. Moderate or severe hypertension. Hyperthyroidism. Glaucoma. Highly nervous or agitated states. Drug or alcohol abuse. Concomitant CNS stimulants. During or within 14 days of MAOIs (see Interactions). |
| Precautions |
|
Discontinue after a few weeks as tolerance to anorectic effect occurs. Avoid abrupt cessation after prolonged high doses. Mild hypertension. Abuse and dependence potential. Diabetes. Reevaluate after drug-free interval. Prescribe minimal supply to avoid overdose. Pregnancy. |
| Interactions |
|
Hypertensive crisis with MAOIs. May antagonize guanethidine. CNS effects with alcohol, other CNS drugs. |
| Adverse Reactions |
|
Palpitation, tachycardia, hypertension, CNS overstimulation, dry mouth, GI disturbances, urinary frequency, changes in libido. |
| How Supplied |
Tabs—100, 1000
Caps—100 |
|
|
|
|
